487 related articles for article (PubMed ID: 32343968)
21. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine.
Fontana F; Alfano G; Mori G; Amurri A; Tei L; Ballestri M; Leonelli M; Facchini F; Damiano F; Magistroni R; Cappelli G
Am J Transplant; 2020 Jul; 20(7):1902-1906. PubMed ID: 32324331
[TBL] [Abstract][Full Text] [Related]
22. Hemophagocytic syndrome: a potential COVID-19 complication.
Amaral LTW; Fonseca EKUN; Jacomelli M; Szarf G; Chate RC
J Bras Pneumol; 2020 Sep; 46(5):e20200296. PubMed ID: 32965311
[No Abstract] [Full Text] [Related]
23. COVID-19 in a Patient With Rheumatoid Arthritis During Tocilizumab Treatment.
Yamada Z; Nanki T
J Clin Rheumatol; 2020 Sep; 26(6):240-241. PubMed ID: 32732527
[No Abstract] [Full Text] [Related]
24. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Liu B; Li M; Zhou Z; Guan X; Xiang Y
J Autoimmun; 2020 Jul; 111():102452. PubMed ID: 32291137
[TBL] [Abstract][Full Text] [Related]
25. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
26. Tocilizumab administration in a refractory case of COVID-19.
Dastan F; Nadji SA; Saffaei A; Tabarsi P
Int J Antimicrob Agents; 2020 Aug; 56(2):106043. PubMed ID: 32502524
[No Abstract] [Full Text] [Related]
27. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia.
Zhang S; Li L; Shen A; Chen Y; Qi Z
Clin Drug Investig; 2020 Jun; 40(6):511-518. PubMed ID: 32337664
[TBL] [Abstract][Full Text] [Related]
28. Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.
Melody M; Nelson J; Hastings J; Propst J; Smerina M; Mendez J; Guru P
Immunotherapy; 2020 Oct; 12(15):1121-1126. PubMed ID: 32546029
[No Abstract] [Full Text] [Related]
29. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience.
Zain Mushtaq M; Bin Zafar Mahmood S; Jamil B; Aziz A; Ali SA
Int Immunopharmacol; 2020 Nov; 88():106926. PubMed ID: 32889236
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.
Campochiaro C; Della-Torre E; Cavalli G; De Luca G; Ripa M; Boffini N; Tomelleri A; Baldissera E; Rovere-Querini P; Ruggeri A; Monti G; De Cobelli F; Zangrillo A; Tresoldi M; Castagna A; Dagna L;
Eur J Intern Med; 2020 Jun; 76():43-49. PubMed ID: 32482597
[TBL] [Abstract][Full Text] [Related]
31. [Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab].
Luo S; Yang L; Wang C; Liu C; Li D
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(2):227-231. PubMed ID: 32391669
[TBL] [Abstract][Full Text] [Related]
32. Takotsubo cardiomyopathy triggered by SARS-CoV-2 infection in a critically ill patient.
Taza F; Zulty M; Kanwal A; Grove D
BMJ Case Rep; 2020 Jun; 13(6):. PubMed ID: 32540884
[TBL] [Abstract][Full Text] [Related]
33. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.
Quartuccio L; Sonaglia A; McGonagle D; Fabris M; Peghin M; Pecori D; De Monte A; Bove T; Curcio F; Bassi F; De Vita S; Tascini C
J Clin Virol; 2020 Aug; 129():104444. PubMed ID: 32570043
[TBL] [Abstract][Full Text] [Related]
34. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
Zhang C; Wu Z; Li JW; Zhao H; Wang GQ
Int J Antimicrob Agents; 2020 May; 55(5):105954. PubMed ID: 32234467
[TBL] [Abstract][Full Text] [Related]
35. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.
Ye Q; Wang B; Mao J
J Infect; 2020 Jun; 80(6):607-613. PubMed ID: 32283152
[TBL] [Abstract][Full Text] [Related]
36. Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report.
Faqihi F; Alharthy A; Alshaya R; Papanikolaou J; Kutsogiannis DJ; Brindley PG; Karakitsos D
BMC Cardiovasc Disord; 2020 Aug; 20(1):389. PubMed ID: 32842957
[TBL] [Abstract][Full Text] [Related]
37. [Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome].
Velasco Puyó P; Moreno L; Díaz de Heredia C; Rivière JG; Soler Palacín P
An Pediatr (Engl Ed); 2020 Aug; 93(2):132-133. PubMed ID: 32593520
[No Abstract] [Full Text] [Related]
38. Title: Cytokine release syndrome is not usually caused by secondary hemophagocytic lymphohistiocytosis in a cohort of 19 critically ill COVID-19 patients.
Lorenz G; Moog P; Bachmann Q; La Rosée P; Schneider H; Schlegl M; Spinner C; Heemann U; Schmid RM; Algül H; Lahmer T; Huber W; Schmaderer C
Sci Rep; 2020 Oct; 10(1):18277. PubMed ID: 33106497
[TBL] [Abstract][Full Text] [Related]
39. Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
Wang L; Peng X; Wang ZH; Cai J; Zhou FC
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5783-5787. PubMed ID: 32495916
[TBL] [Abstract][Full Text] [Related]
40. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.
Soy M; Keser G; Atagündüz P; Tabak F; Atagündüz I; Kayhan S
Clin Rheumatol; 2020 Jul; 39(7):2085-2094. PubMed ID: 32474885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
